Study Title
LGG Avastin: A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma
Protocol ID
OZM-063 (LGG Avastin)
Disease (Sub Disease)
Low Grade Glioma
Diagnosis Stage
New diagnosis
Relapse/ refractory
Relapse/ refractory
Location
NSW, QLD, VIC, WA, SA
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
The Hospital for Sick Children
The Hospital for Sick Children
Collaborators
Hoffmann-La Roche
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Women's & Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Royal Children's Hospital
Women's & Children's Hospital
Study Type
Treatment
Phase
Phase 2
Age Eligibility
6 months to 18 years old
International registry ID's
NCT02840409
| Study Title | LGG Avastin: A phase II & open-labeled & multi-center & randomized controlled trial of Vinblastine +/- Bevacizumab for the treatment of chemotherapy-naive children with unresectable or progressive low grade glioma |
|---|---|
| Protocol ID | OZM-063 (LGG Avastin) |
| Disease (Sub Disease) | Low Grade Glioma |
| Diagnosis Stage | New diagnosis Relapse/ refractory |
| Location | NSW / QLD / VIC / WA / SA |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ The Hospital for Sick Children |
| Collaborators | Hoffmann-La Roche |
| Links | https://clinicaltrials.gov/ct2/show/NCT02840409 |
| Trial Status | Open |
| Trial Open Date | 29/05/2018 |
| Sites | The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Royal Children's Hospital / Women's & Children's Hospital / |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 6 months to 18 years old |
| International registry ID's | NCT02840409 |